Status: Not yet recruiting
Guo&Amp;'s Distal Entry Tear Repair With WeFlow-EndoPatch System (Gallant Study)
A Multicenter, Randomized Controlled Study About the Safety and Efficacy of WeFlow-EndoPatch Aortic Endovascular Patch System manufactured by EndoNom Medtech (Hangzhou) Co., Ltd. for Chronic Aortic Dissection . (GALLANT Study)
Participants needed: 204
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Hangzhou Endonom Medtech Co., Ltd.Updated: Apr 30, 2025
Eligibility criteria
Patients aged 18 to 80 years old, no gender limitation; [+5]
Rupture or threatened rupture of aortic dissection; [+15]